Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (ARRECTOR)

A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR)

This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.

Study Overview

• Status: Completed
• Conditions: Scalp Psoriasis
• Intervention / Treatment: Drug: Roflumilast Foam 0.3%; Drug: Vehicle Foam

Detailed Description

This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle foam is applied once daily for 8 weeks to subjects with scalp and body psoriasis.

• Study Type: Interventional
• Enrollment (Actual): 432
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2J 7E1
      • Arcutis Biotherapeutics Clinical Site 35
  • British Columbia
    • Surrey, British Columbia, Canada, V3V0C6
      • Arcutis Biotherapeutics Clinical Site 37
  • Manitoba
    • Winnepeg, Manitoba, Canada, R3M 3Z4
      • Arcutis Biotherapeutics Clinical Site 47
  • New Brunswick
    • Fredericton, New Brunswick, Canada, E3B 1G9
      • Arcutis Biotherapeutics Clinical Site 43
  • Ontario
    • Ajax, Ontario, Canada, L1S 7K8
      • Arcutis Biotherapeutics Clinical Site 38
    • London, Ontario, Canada, N6H 5L5
      • Arcutis Biotherapeutics Clinical Site 16
    • Mississauga, Ontario, Canada, L5H 1G9
      • Arcutis Biotherapeutics Clinical Site 29
    • North Bay, Ontario, Canada, P1B 3Z7
      • Arcutis Biotherapeutics Clinical Site 30
    • Peterborough, Ontario, Canada, K9J 5K2
      • Arcutis Biotherapeutics Clinical Site 32
    • Toronto, Ontario, Canada, M4W 2N2
      • Arcutis Biotherapeutics Clinical Site 71
    • Waterloo, Ontario, Canada, N2J 1C4
      • Arcutis Biotherapeutics Clinical Site 36
    • Windsor, Ontario, Canada, N8W 1E6
      • Arcutis Biotherapeutics Clinical Site 49
  • Quebec
    • Montreal, Quebec, Canada, H3Z 2S6
      • Arcutis Biotherapeutics Clinical Site 09
• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85255
      • Arcutis Biotherapeutics Clinical Site 01
  • California
    • Beverly Hills, California, United States, 90212
      • Arcutis Biotherapeutics Clinical Site 50
    • Encinitas, California, United States, 92024
      • Arcutis Biotherapeutics Clinical Site 45
    • San Diego, California, United States, 92123
      • Arcutis Biotherapeutics Clinical Site 64
    • Santa Ana, California, United States, 92701
      • Arcutis Biotherapeutics Clinical Site 72
    • Santa Monica, California, United States, 90404
      • Arcutis Biotherapeutics Clinical Site 21
  • Florida
    • Clearwater, Florida, United States, 33756
      • Arcutis Biotherapeutics Clinical Site 33
    • Coral Gables, Florida, United States, 33134
      • Arcutis Biotherapeutics Clinical Site 42
    • Delray Beach, Florida, United States, 33484
      • Arcutis Biotherapeutics Clinical Site 57
    • North Miami Beach, Florida, United States, 33162
      • Arcutis Biotherapeutics Clinical Site 31
    • Orlando, Florida, United States, 32819
      • Arcutis Biotherapeutics Clinical Site 05
    • Sanford, Florida, United States, 32771
      • Arcutis Biotherapeutics Clinical Site 65
    • Tampa, Florida, United States, 33613
      • Arcutis Biotherapeutics Clinical Site 12
  • Illinois
    • Plainfield, Illinois, United States, 46168
      • Arcutis Biotherapeutics Clinical Site 22
    • Rolling Meadows, Illinois, United States, 60008
      • Arcutis Biotherapeutics Clinical Site 10
  • Kentucky
    • Louisville, Kentucky, United States, 40217
      • Arcutis Biotherapeutics Clinical Site 15
  • Louisiana
    • Lake Charles, Louisiana, United States, 70605
      • Arcutis Biotherapeutics Clinical Site 04
  • Maryland
    • Rockville, Maryland, United States, 20850
      • Arcutis Biotherapeutics Clinical Site 02
    • Rockville, Maryland, United States, 20850
      • Arcutis Biotherapeutics Clinical Site 28
  • Michigan
    • Detroit, Michigan, United States, 48202
      • Arcutis Biotherapeutics Clinical Site 20
  • Minnesota
    • New Brighton, Minnesota, United States, 55112
      • Arcutis Biotherapeutics Clinical Site 14
  • Missouri
    • Saint Joseph, Missouri, United States, 64506
      • Arcutis Biotherapeutics Clinical Site 44
  • New Jersey
    • East Windsor, New Jersey, United States, 08520
      • Arcutis Biotherapeutics Clinical Site 34
  • New York
    • Bronx, New York, United States, 10462
      • Arcutis Biotherapeutics Clinical Site 63
    • Rochester, New York, United States, 14623
      • Arcutis Biotherapeutics Clinical Site 51
  • North Carolina
    • High Point, North Carolina, United States, 27262
      • Arcutis Biotherapeutics Clinical Site 23
  • Oregon
    • Portland, Oregon, United States, 97223
      • Arcutis Biotherapeutics Clinical Site 25
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • Arcutis Biotherapeutics Clinical Site 27
  • Tennessee
    • Knoxville, Tennessee, United States, 37922
      • Arcutis Biotherapeutics Clinical Site 06
  • Texas
    • Arlington, Texas, United States, 76011
      • Arcutis Biotherapeutics Clinical Site 13
    • Austin, Texas, United States, 78759
      • Arcutis Biotherapeutics Clinical Site 11
    • College Station, Texas, United States, 77845
      • Arcutis Biotherapeutics Clinical Site 41
    • San Antonio, Texas, United States, 78213
      • Arcutis Biotherapeutics Clinical Site 54
    • San Antonio, Texas, United States, 78218
      • Arcutis Biotherapeutics Clinical Site 24
  • Utah
    • West Jordan, Utah, United States, 84088
      • Arcutis Biotherapeutics Clinical Site 07
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Arcutis Biotherapeutics Clinical Site 17

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• For adult subjects: Participants legally competent to read, write, and sign and give informed consent. For adolescent subjects: Informed consent of a parent(s) or legal guardian, and assent by the subjects, as required by local laws.
• Males and females ages 12 years and older (inclusive) at the time of consent or assent.
• Scalp psoriasis with a Scalp-Investigator Global Assessment of Disease (S IGA) severity of at least Moderate ('3') at Baseline.
• Extent of scalp psoriasis involving ≥ 10% of the total scalp at Baseline.
• A Psoriasis Scalp Severity Index (PSSI) of at least 6 at Baseline.
• An IGA of body (i.e., non-scalp) psoriasis (B-IGA) of at least Mild ('2') at Baseline.
• A PASI score of at least 2 (excluding palms and soles) at Baseline.
• Clinical diagnosis of psoriasis vulgaris of at least 6 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks.
• Total overall psoriasis involvement on scalp and non-scalp areas ≤ 25% BSA (not including palms/soles) at Baseline. Total non-scalp BSA should not exceed 20%.
• Female subject of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and negative urine pregnancy test at Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception or a barrier method of contraception throughout the study according to Contraception Requirements for the protocol.
• Females of non-childbearing potential must either be premenarchal, post-menopausal with spontaneous amenorrhea for at least 12 months (post-menopausal status will be confirmed with FSH testing) or have undergone surgical sterilization according to Contraception Requirements for the protocol. Prepubescent females must agree to be abstinent during the study.
• Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.

Exclusion Criteria:

• Subjects who cannot discontinue treatment with therapies for the treatment of psoriasis vulgaris prior to the Baseline visit and during the study.
• Planned excessive exposure to treated area(s) to either natural or artificial sunlight, tanning bed, or other LED.
• Previous treatment with ARQ-151 or ARQ-154.
• Females who are pregnant, wishing to become pregnant during the study, or are breast feeding.
• Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
• Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects.
• Any condition that in the Investigator's assessment would preclude the subject from participating in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Roflumilast Foam 0.3%; Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% once daily (qd) for 8 weeks.	Drug: Roflumilast Foam 0.3%; Roflumilast foam 0.3%; Other Names: ARQ-154 0.3%
Placebo Comparator: Vehicle Foam; Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.	Drug: Vehicle Foam; Vehicle foam matched to roflumilast 0.3% foam.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8	The percentage of participants with S-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.	Week 8
Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 8	The percentage of participants with B-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.	Week 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Achievement of Scalp Itch-Numeric Rating Score (SI-NRS ) Success at Week 2	The percentage of participants with SI-NRS success at Week 2 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.	Week 2
Achievement of SI-NRS Success at Week 4	The percentage of participants with SI-NRS success at Week 4 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.	Week 4
Achievement of SI-NRS Success at Week 8	The percentage of participants with SI-NRS success at Week 8 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.	Week 8
Change From Baseline in SI-NRS Score at Day 1	SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.	Day 1
Change From Baseline in SI-NRS Score at Day 3	SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.	Day 3
Change From Baseline in SI-NRS Score at Week 1	SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.	Week 1
Achievement of WI-NRS (Worst Itch-Numeric Rating Score) Success at Week 8	WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from 0 ("no itch") to 10 ("worst imaginable itch"). Success is defined as achievement of a ≥ 4-point improvement from baseline in participants with a baseline WI-NRS pruritus score of ≥ 4.	Week 8
Achievement of a 75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)	The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.	Week 8
Change From Baseline in Psoriasis Symptoms Diary (PSD) Aggregate Score of Itching, Pain, and Scaling (Questions 1, 9, and 11)	The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The aggregate Itching, Pain, and Scaling score ranges from 0 to 30; the change from baseline in aggregate score was assessed per protocol only in adult participants.	Week 8
Percentage of Participants Achieving PSD Itching (Question 1) Score of 0 at Week 8	The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.	Week 8
Percentage of Participants Achieving PSD Pain (Question 9) Score of 0 at Week 8	The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Pain score ranges from 0 to 10.	Week 8
Percentage of Participants Achieving PSD Scaling (Question 11) Score of 0 at Week 8	The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.	Week 8
Percentage of Participants Achieving PSD Total Score of 0 at Week 8		Week 8
Achievement of a 75% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI) Score (PSSI-75)	The PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease). PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).	Week 8
Achievement of S-IGA Score of 'Clear' at Week 8	The percentage of participants with S-IGA score of 0 Week 8 is presented. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.	Week 8
Achievement of S-IGA Success at Week 2	The percentage of participants with S-IGA success at Week 2 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.	Week 2
Achievement of S-IGA Success at Week 4	The percentage of participants with S-IGA success at Week 4 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.	Week 4
Change From Baseline in PASI Score at Week 2	The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.	Week 2

Collaborators and Investigators

• Sponsor: Arcutis Biotherapeutics, Inc.
• Investigators: Study Director: David Berk, MD, Arcutis Biotherapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): August 24, 2021
• Primary Completion (Actual): June 3, 2022
• Study Completion (Actual): June 3, 2022

Study Registration Dates

• First Submitted: August 25, 2021
• First Submitted That Met QC Criteria: August 25, 2021
• First Posted (Actual): August 31, 2021

Study Record Updates

• Last Update Posted (Actual): July 17, 2025
• Last Update Submitted That Met QC Criteria: July 16, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases, Papulosquamous; Skin Diseases; Psoriasis
• Other Study ID Numbers: ARQ-154-309

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No